Akebia Therapeutics Inc. (AKBA) Business Metric Overview - Stocknear

Akebia Therapeutics Inc.

NASDAQ: AKBA · Real-Time Price · USD
2.96
-0.06 (-1.99%)
At close: Sep 05, 2025, 3:59 PM
2.97
0.34%
Pre-market: Sep 08, 2025, 07:00 AM EDT

Akebia Therapeutics Revenue Breakdown

Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018
License Collaboration And Other Revenue Revenue 2.01M 1.54M 4.57M 1.84M 2.44M 1.6M 4.89M 1.93M 14.13M 5.3M 5.71M 6.72M 83.06M 20.25M 29.13M 12M 19.95M 21.9M 22.09M 25.6M 59.45M 59.27M 40.64M 30M 10M 23.11M 53.03M
License Collaboration And Other Revenue Revenue Growth +30.16% -66.16% +148.69% -24.72% +52.63% -67.33% +153.68% -86.36% +166.69% -7.28% -15.02% -91.90% +310.13% -30.48% +142.70% -39.85% -8.87% -0.90% -13.68% -56.94% +0.30% +45.84% +35.45% +200.04% -56.73% -56.42% n/a
Product Revenue 60.46M 55.79M 85.58M 35.59M 41.21M 31.01M 93.23M 40.12M 42.24M 34.83M 49.68M 42.24M 43.7M 41.45M 42.1M 36.75M 32.96M 30.41M 34.6M 34.39M 30.7M 29.21M 28.91M n/a n/a n/a n/a
Product Revenue Growth +8.37% -34.81% +140.44% -13.63% +32.89% -66.74% +132.39% -5.03% +21.29% -29.89% +17.61% -3.35% +5.44% -1.54% +14.54% +11.51% +8.39% -12.13% +0.62% +12.04% +5.09% +1.02% n/a n/a n/a n/a n/a

Operating Expense Breakdown

Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selling, General, and Administrative Revenue 26.55M 25.74M 27.68M 26.52M 27.68M 26.15M 26.29M 22.71M 27.04M 25.22M 29.91M 31.66M 33.7M 45.02M 44.8M 47.23M 42.55M 42.02M 40.31M 40.88M 36.53M 38.66M 44.92M 34.18M 36.96M 34.29M 55.12M 10.38M 12.54M 9.02M 7.57M 6.75M 6.91M 5.79M 6.14M 4.94M 5.31M 5.81M 7.51M 3.89M 3.71M 3.39M
Selling, General, and Administrative Revenue Growth +3.16% -6.98% +4.37% -4.20% +5.85% -0.54% +15.76% -16.00% +7.20% -15.67% -5.54% -6.05% -25.14% +0.47% -5.13% +11.00% +1.24% +4.25% -1.39% +11.92% -5.52% -13.93% +31.42% -7.53% +7.79% -37.79% +431.13% -17.23% +38.94% +19.25% +12.14% -2.27% +19.30% -5.79% +24.27% -6.91% -8.60% -22.63% +93.18% +4.88% +9.32% n/a
Research and Development Revenue 11.01M 9.75M 11.79M 8.49M 7.25M 9.37M 9.47M 13.33M 20.2M 19.69M 31.9M 27.35M 26.03M 43.83M 29.56M 40.47M 37.21M 40.61M 37.58M 46.86M 52.82M 81.23M 80.41M 74.51M 85.69M 82.35M 87.11M 70.63M 71.92M 61.4M 68.38M 58.71M 43.75M 60.05M 33.44M 31.24M 30.88M 20.23M 12.54M 15.79M 7.18M 7.5M
Research and Development Revenue Growth +12.91% -17.24% +38.87% +17.09% -22.62% -1.11% -28.94% -34.00% +2.60% -38.30% +16.65% +5.08% -40.62% +48.30% -26.97% +8.75% -8.36% +8.07% -19.80% -11.29% -34.98% +1.02% +7.92% -13.05% +4.06% -5.47% +23.33% -1.78% +17.12% -10.20% +16.47% +34.19% -27.14% +79.60% +7.03% +1.17% +52.59% +61.38% -20.59% +119.86% -4.30% n/a